Elafibranor, also known as GFT-505, is a dual PPARα/δ agonist. Elafibranoris currently being studied for the treatment of cardiometabolic diseases including diabetes, insulin resistance, dyslipidemia, and non-alcoholic fatty liver disease (NAFLD).
Contact：Wuhan Sun-shineBio-technologyCorporation Limited Add: Building C16, No.388Gaoxin 2Road, East Lake Hi-tech Development Zone, Wuhan 430200, China Tel: +86-27-65522452 QQ：1973737790 Web:http://www.sun-shinechem.com
| 
_923978-27-2.png)